Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Sep 13 - Sep 18
[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
With hormone suppression, the probability of lesion progression is not zero but is significantly lower than with expectant management [56]
it became something we could actually test only later, which is precisely why the structured downtitration and rechallenge were done
But we shouldnt be surprised
ReverberiM.RicelliA.ZjalicS.FabbriA
US$ 28.58
US$ 21.95
US$ 24.31
US$ 27.43
